Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 46, Issue 2, 1998, Pages 223-228

  Gasser, U E ^a   Crevoisier, Ch ^b   Ouwerkerk, M ^c   Lankhaar, G ^c   Dingemanse, J ^c  

^a Roche Pharma Schweiz AG   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Clin Pharma Research AG   (Switzerland)

Author keywords

Dual release formulation; Levodopa; Multiple dose; Parkinson's disease; Pharmacokinetics

Indexed keywords

BENSERAZIDE PLUS LEVODOPA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE FORMULATION; VOLUNTEER;

BENSERAZIDE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FASTING; HUMANS; LEVODOPA; METABOLIC CLEARANCE RATE; TIME FACTORS; TYROSINE;

EID: 0031688961     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(98)00022-8     Document Type: Article

References (23)

1. S. Harder, H. Baas, H. Bergemann, L. Demisch, S. Rietbrock, Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a slow-release formulation, Br. J. Clin. Pharmacol. 39 (1995) 39-44.
2. S. Harder, H. Baas, S. Rietbrock, Concentration-effect relationship of levodopa in patients with Parkinson's disease, Clin. Pharmacokinet. 29 (1995) 243-256.
3. P.A. Kempster, J.P. Frankel, M. Bovingdon, R. Webster, A.J. Lees, G.M. Stern, Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease, J. Neurol. Neurosurg. Psychiatry 52 (1989) 718-723.
4. M.D. Muenter, N.S. Sharpless, G.M. Tyce, Plasma 3-O-methyldopa in levodopa therapy of Parkinson's disease, Mayo Clin. Proc. 47 (1972) 389-395.
5. Ch. Crevoisier, B. Hoevels, G. Zürcher, M. Da Prada, Bioavailability of levodopa after Madopar HBS administration in healthy subjects, Eur. Neurol. 27 (suppl. 1) (1987) 36-46.
6. A. Grahnén, S.A. Eckernäs, C. Collin, A. Ling-Andersson, G. Tiger, M. Nilsson, Comparative multiple-dose pharmacokinetics of slow-release levodopa products, Eur. Neural. 32 (1992) 343-348.
7. U.K. Rinne, J.O. Rinne, Madopar HBS in the treatment of early Parkinson's disease, in: A. Agnoli, G. Campanella (Eds.), New Developments in Therapy of Parkinson's Disease, John Libbey CIC, Rome, 1991, pp. 17-22.
8. E.N.H. Jansen, J.D. Meerwaldt, Madopar HBS in Parkinson patients with nocturnal akinesia, Clin. Neurol. Neurosurg. 90 (1988) 35-39.
9. E.N.H. Jansen, J.D. Meerwaldt, Madopar HBS in nocturnal symptoms of Parkinson's disease, Adv. Neurol. 53 (1990) 527-531.
10. C. Trenkwalder, M. Wagner, T. Gasser, W. Poewe, W.H. Oertel, Long-term treatment with slow-release levodopa (Madopar HBS) in Parkinsonian patients with nocturnal disabilities, in: A. Agnoli, G. Campanella (Eds.), New Developments in Therapy of Parkinson's Disease, John Libbey CIC, Rome, 1991, pp. 22-27.
11. W.H. Poewe, A.J. Lees, G.M. Stern, Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of levodopa: clinical and pharmacokinetic observations, Clin. Neuropharmacol. 9 (1986) 430-439.
12. U.K. Rinne, Madopar HBS in the long-term treatment of Parkinsonian patients with fluctuations in disability, Eur. Neurol. 27 (suppl. 1) (1987) 120-125.
13. F. Stocchi, I. Giorgi, D. Bravi, S. Ruggieri, A. Monge, L. Bramanta, A. Agnoli, A multicenter trial with Madopar HBS in fluctuatory Parkinsonian patients, in: A. Agnoli, G. Campanella (Eds.), New Developments in Therapy of Parkinson's Disease, John Libbey CIC, Rome, 1991, pp. 29-32.
14. R. Kurlan, J.G. Nutt, W.R. Woodward, K. Rothfield, D. Lichter, C. Miller, J.H. Carter, I. Shoulson, Duodenal and gastric delivery of levodopa and parkinsonism, Ann. Neurol. 23 (1988) 589-595.
15. E. Schneider, B. Ziegler, Levodopa-Therapie und Ernährung beim Parkinson-Syndrom, Neurol. Psychiatr. Schweiz 2 (1991) 109-115.
16. K.C. Yeh, T.F. August, D.F. Bush, K.C. Lasselet, D.G. Musson, S. Schwartz, M.E. Smith, D.C. Titus, Pharmacokinetics and bioavailability of Sinemet CR: summary of human studies, Neurology 39 (suppl. 2) (1989) 25-37.
17. G. Heinzel, R. Woloszczak, P. Thomann, TopFit 2.0 Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC, Gustav Fischer, Stuttgart, 1993.
18. M. Contin, R. Riva, P. Martinelli, P. Cortelli, F. Albani, A. Baruzzi, Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease, Neurology 43 (1993) 367-371.
19. J. Dingemanse, C.H. Kleinbloesem, G. Lankhaar, Ch. Crevoisier, U.E. Gasser, Pharmacokinetic studies with a new dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease, Eur. Neurol. 39 (1998) 119-124.
20. M.V. Nelson, R.C. Berchou, P.A. LeWitt, D. Kareti, M.P. Galloway, Pharmacodynamic modeling of concentration-effect relationships after slow-release carbidopa/levodopa (Sinemet CR4) in Parkinson's disease, Neurology 40 (1990) 70-74.
21. L.A. Wade, R. Katzman, 3-O-Methyldopa uptake and inhibition of levodopa at the blood-brain barrier, Life Sci. 17 (1975) 131-136.
22. L. Rivera-Calimlim, T. Deepak, R. Anderson, R. Joynt, The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders, Arch. Neurol. 34 (1977) 228-232.
23. J. Ghika, J.P. Gachoud, U.E. Gasser and the L-Dopa Dual-Release Study Group, Clinical efficacy and tolerability of a new Levodopa/ Benserazide Dual-Release formulation in Parkinsonian patients, Clin. Neuropharm. 20 (1997) 130-139.